Company intelligence / Profile preview
Immutep Limited
Sydney, New South Wales, Australiaimmutep.com ↗
- Ownership
- Public · IMMP
- Employees
- ~31
- Development stage
- Phase 3
01
Overview
Immutep is conducting a pivotal Phase III trial (TACTI-004/KEYNOTE-PNC-91) of efti in combination with KEYTRUDA and chemotherapy in 1L NSCLC. The company has shown impressive clinical results and successfully scaled up manufacturing to commercial levels (2,000L) with regulatory authorization for use in clinical trials across multiple countries.
- Therapeutic areas
- OncologyImmunology
- Modalities
- LAG-3 ImmunotherapyAntibodiesFusion proteinsSmall molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
04
Financials
- Market cap
- $19.8M
- Total revenue
- $9.8M
- Enterprise value
- $-26.8M
Beyond the preview
Go deeper on Immutep Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immutep Limited.